{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002064392,0.0005330665,0.002960226,0.0004339548,0.00009538966,0.000008070926,0.0007205194,0.0005535769,0.002589833],"category_scores_gemma":[0.0001475793,0.0003230261,0.0002541678,0.001396302,0.000832185,0.0000922792,0.0002651295,0.00351312,0.000002659887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008208654,"about_ca_system_score_gemma":0.003330751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007537144,"about_ca_topic_score_gemma":0.0002997642,"domain_scores_codex":[0.9942975,0.001702996,0.001300852,0.0007543794,0.001220822,0.0007234372],"domain_scores_gemma":[0.9966825,0.001924986,0.0005179649,0.0005304267,0.0001002741,0.0002438894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006390557,0.000437394,0.000664869,0.003933098,0.0001329482,0.0001824082,0.0006514434,0.000003884583,0.0000010681,0.0001051059,0.00004243674,0.9932063],"study_design_scores_gemma":[0.002482198,0.0009977864,0.0006097439,0.007690889,0.0001501441,0.0003782237,0.0005722809,0.00005377455,0.000001209777,0.0001738635,0.9866175,0.0002723619],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001782786,0.9905878,0.000009665972,0.005139107,0.001378048,0.002079253,0.00009825947,0.00002846283,0.0005010656],"genre_scores_gemma":[0.0003421452,0.9961335,0.00007811446,0.0007354954,0.001183982,0.00133829,0.00008217014,0.00008319227,0.00002309159],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9929339,"threshold_uncertainty_score":0.9999222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05377138215085864,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}